What is PharmaJet?
PharmaJet operates at the intersection of medical technology and public health, specializing in the development of needle-free injection systems. The company's core value proposition lies in its ability to mitigate risks associated with traditional sharps, including needle-stick injuries, cross-contamination, and the logistical burden of medical waste disposal. By positioning its proprietary injectors as a safer, more efficient alternative to conventional syringes, PharmaJet is actively working to establish its technology as the global standard of care. This market-leading approach is supported by a robust history of private equity and debt financing, enabling the firm to transition from early-stage development to a mature enterprise-level entity capable of addressing large-scale immunization challenges.
How much funding has PharmaJet raised?
PharmaJet has raised a total of $38.7M across 10 funding rounds:
Unspecified
$9.1M
Unspecified
$4.2M
Unspecified
$3.4M
Unspecified
$2.8M
Unspecified
$2.2M
Unspecified
$2.5M
Unspecified
$5.2M
Private Equity
$6M
Private Equity
$3M
Debt
$283K
Unspecified (2009): $9.1M, investors not publicly disclosed
Unspecified (2011): $4.2M, investors not publicly disclosed
Unspecified (2011): $3.4M, investors not publicly disclosed
Unspecified (2012): $2.8M, investors not publicly disclosed
Unspecified (2012): $2.2M, investors not publicly disclosed
Unspecified (2013): $2.5M, investors not publicly disclosed
Unspecified (2013): $5.2M, investors not publicly disclosed
Private Equity (2015): $6M, investors not publicly disclosed
Private Equity (2017): $3M, investors not publicly disclosed
Debt (2021): $283K backed by PPP
Key Investors in PharmaJet
PPP
Public-Private Partnership
Undisclosed Investor
An institutional backer participating in the funding round, focused on long-term value creation within the medical device and healthcare technology sectors.
Undisclosed Investor
A private equity partner providing strategic capital to facilitate the company's transition toward enterprise-level market dominance.
What's next for PharmaJet?
With the recent influx of capital, PharmaJet is well-positioned to accelerate its international expansion and deepen its penetration into the vaccine delivery market. The strategic focus will likely shift toward scaling manufacturing capabilities to meet the rising demand for safe, high-throughput immunization solutions. Furthermore, the company is expected to leverage this financial runway to enhance its R&D pipeline, potentially exploring new applications for its needle-free platform beyond current vaccine delivery protocols. As the firm matures, maintaining its competitive edge will require continued regulatory engagement and the strengthening of its global supply chain, ensuring that its technology remains accessible in both developed and emerging healthcare markets.
See full PharmaJet company page
